Completes purchase of 1.98 mil. shares of newly-issued SyStemix stock at $56 per share. The purchase is in addition to the $280.8 mil. Sandoz will pay for 60% of the stem cell and megakaryocyte company and was part of the original acquisition agreement ("The Pink Sheet" Dec. 23, p. 1). Sandoz also names six members to the SyStemix board of directors: Sandoz Pharma chairman Max Link, PhD; corporate R&D head Stefan Guttmann; Vice Chairman and CEO of Sandoz Corp. Daniel Wagniere; Sandoz Research Institute President Robert Levy, MD; SRI Senior VP-Preclinical Research Jurg Meier, PhD; and the CEO of Sandoz' Austrian Research Institute Peter Dukor, MD.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth